Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.
Simon JA, Kingsberg SA, Portman D, Jordan R, Lucas J, Sadiq A, Krop J, Clayton AH.
Simon JA, et al.
J Womens Health (Larchmt). 2022 Mar;31(3):391-400. doi: 10.1089/jwh.2021.0225. Epub 2022 Feb 25.
J Womens Health (Larchmt). 2022.
PMID: 35230162
Clinical Trial.
This report investigates efficacy of bremelanotide versus placebo according to prespecified subgroups (age, weight, body mass index [BMI], and bioavailable testosterone) in the RECONNECT studies. Materials and Methods: Patients self-administered bremelanotide 1.75 m …
This report investigates efficacy of bremelanotide versus placebo according to prespecified subgroups (age, weight, body mass index [ …